RE:RE:RE:RE:RE:RE:Sales breakdownMy understanding is that if a product is already approved in Europe and/or other jurisdictions that the HC is somewhat of a formality... I would expect approval at end of the year.
While 2015 revenues were $15.4m one mustn't forget that RX hasn't come close to reaching peak penetration revs on many of their current products.
I also wouldn't be surprised to see more announcements on the biz development front through balance of 2016. They spent 2015 moving to new office and adding sale and marketing bench strength. I can easily see RX testing previous highs of $12 within next two years.
This is a very well run and easy to understand biz.
I just hope they don't get acquired!